Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:00 AM
Ignite Modification Date:
2025-12-25 @ 2:00 AM
NCT ID:
NCT01254994
Eligibility Criteria:
Inclusion Criteria:
* ACHBLF was diagnosed according to the criteria from the APASL in March 200815 and the program of Prevention and Cure for Viral Hepatitis and Liver Disease amended by the National Symposium on Viral Hepatitis and Liver Disease in September 2000.
* age \>18 years
* HBV DNA \> 3log10 copy/mL
Exclusion Criteria:
* Pregnant or lactating women.
* Diagnosed or suspected as hepatic carcinoma patients.
* Cases with any serious disease besides CHB, including heart disease, immunologic disease, malignant tumor, etc.
* Patients hypersensitive to nucleoside or nucleoside (acid) analogues or with a history nucleoside antiviral drug treatment.
* A history of drug abuse or alcohol abuse.
* Hepatic encephalopathy degree IV patients who were unable to take orally administered drugs.
* A history of using immunomodulator including steroids
* Conclusive evidence of other co infection s: anti-HAV-IgM positive, anti-HCV positive, anti-HEV positive, anti-HIV positive, autoimmunity liver diseases, Wilson disease, etc.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01254994
Study Brief:
Protocol Section:
NCT01254994